Industry: Biopharmaceutical Region: South Korea Transaction price: $10 million Transaction method: equity investment
The Korean pharmaceutical company was founded in 1941, went public in 1975, and was separated from the parent company in August 2016. It has more than 1,400 employees and more than 200 r&d personnel, with annual sales of more than 4 billion US dollars and profit of more than 400 million US dollars.
Details: The South Korean pharmaceutical company was founded in 1941, went public in 1975 and was spun off from its parent company in August 2016. It has more than 1,400 employees and more than 200 r&d staff, with annual sales of more than $4 billion and profits of more than $400 million.
The company owns a number of brands such as chronic disease treatment drugs, anti-cancer drugs, antibiotics, digestive and circulatory system treatment drugs, and has developed new drugs such as hepatitis B treatment drugs, owns many new drugs pipeline, and has a high reputation in South Korea. The company is also involved in the health and functional food, medical equipment, cosmetics, food and other big health fields, and research and development of lactic acid bacteria, multi-vitamins and other nutritional products.
Cooperation intention
The company wants to license the patented technology for some products, including:
Type 2 diabetes drug GPR40 agonist technology
FXR agonist technology for nonalcoholic steatohepatitis (NASH)
Non-alcoholic fatty Cirrhosis (NASH-Cirrhosis) ATX inhibitor technology
VEGFA/NRP1 dual-targeting Fab for wAMD technology